• linkedin
  • Increase Font
  • Sharebar

    10 More Newly Approved Drugs

    The FDA is having a productive 2017.


    Brineura bottles

    BRINEURA (cerliponase alfa), BioMarin

    Indications: A hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.

    Dosage: Injection: Brineura 150 mg/5 mL (30 mg/mL) solution, two single-dose vials per carton co-packaged with Intraventricular Electrolytes Injection 5 mL in a single-dose vial. Brineura is administered to the cerebrospinal fluid by infusion via a surgically implanted reservoir and catheter.

    Contraindications: Acute complications related to the intraventricular access device(e.g., leakage, device failure, or device-related infection) or patients with ventriculoperitoneal shunts.

    Read the prescribing information here

    Previous ButtonNext Button



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available